954 results on '"Mansur, Rodrigo B"'
Search Results
2. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
3. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
4. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists
5. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
6. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
7. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)
8. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
9. Association between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis
10. Central effects of acute intranasal insulin on neuroimaging, cognitive, and behavioural outcomes: A systematic review
11. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
12. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
13. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
14. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
15. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
16. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review
17. Peripheral inflammatory biomarkers define biotypes of bipolar depression
18. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
19. Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders
20. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
21. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis
22. Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD
23. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity
24. Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
25. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis
26. Evaluating cognitive function in unaffected relatives of individuals with bipolar disorders: A meta-analysis
27. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies
28. Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
29. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis
30. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
31. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects
32. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the united states food and drug administration adverse event reporting system (FAERS)
33. 271. Maintenance Ketamine Infusions Demonstrate Sustained Antidepressant Efficacy in a Real-World Treatment-Resistant Unipolar and Bipolar Depression Sample
34. Impact of Elevated Body Mass Index (BMI) on Cognitive Functioning and Inflammation in Persons with Post-COVID-19 Condition: A Secondary Analysis
35. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
36. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
37. Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
38. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)
39. The Prevalence of Suicidal Behaviour in Fibromyalgia Patients
40. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence
41. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment
42. Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression.
43. The impact of overweight/obesity on monetary reward processing: A systematic review
44. A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat
45. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence
46. Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application
47. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence
48. Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9)
49. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions
50. Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.